Your browser doesn't support javascript.
loading
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia.
Seber, Adriana; de CastroJunior, Claudio Galvão; Kerbauy, Lucila N; Hirayama, Alexandre V; Bonfim, Carmem; Fernandes, Juliana Folloni; Souza, Mair; Schafell, Rony; Nabhan, Samir; Loggetto, Sandra Regina; Simões, Belinda Pinto; Rocha, Vanderson; de Lima, Marcos; Guerino-Cunha, Renato L; Bittencourt, Henrique.
Afiliación
  • Seber A; Hospital Samaritano Higienópolis, São Paulo, SP, Brazil; Hospital Infantil Sabará, São Paulo, SP, Brazil.
  • de CastroJunior CG; Hemomed Instituto de Oncologia e Hematologia, São Paulo, SP, Brazil; Hospital São Camilo, São Paulo, SP, Brazil.
  • Kerbauy LN; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
  • Hirayama AV; Fred Hutchinson Cancer Research Center, Seattle, WA, EUA.
  • Bonfim C; Hospital Pequeno Príncipe, Curitiba, PR, Brazil; Hospital de Clínicas, Universidade Federal do Paraná (HC UFPR), Curitiba, PR, Brazil.
  • Fernandes JF; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Instituto do Tratamento do Câncer Infantil, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC FMUSP), São Paulo, SP, Brazil.
  • Souza M; Hospital Amaral Carvalho, Jaú, SP, Brazil.
  • Schafell R; Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro (HUCFF UFRJ), Rio de Janeiro, RJ, Brazil.
  • Nabhan S; Hospital de Clínicas - Universidade Federal do Paraná, (HC UFPR), Curitiba, PR, Brazil.
  • Loggetto SR; Hospital Infantil Sabará, São Paulo, SP, Brazil; Grupo Gestor de Serviços de Hematologia (GSH), São Paulo, SP, Brazil.
  • Simões BP; Kolb Consulting UG, Munich, Germany.
  • Rocha V; Hospital das Clínicas, Universidade de São Paulo, (HC USP), São Paulo, SP, Brazil; Hospital Vila Nova Star, São Paulo, SP, Brazil.
  • de Lima M; Ohio State University, Columbus, OH, USA.
  • Guerino-Cunha RL; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil. Electronic address: rlgc@usp.br.
  • Bittencourt H; Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Qc, Canada; Université de Montreal, Montreal, Qc, Canada.
Hematol Transfus Cell Ther ; 43 Suppl 2: S13-S21, 2021 Nov.
Article en En | MEDLINE | ID: mdl-34794791
Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline País/Región como asunto: America do sul / Brasil Idioma: En Revista: Hematol Transfus Cell Ther Año: 2021 Tipo del documento: Article País de afiliación: Brasil
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline País/Región como asunto: America do sul / Brasil Idioma: En Revista: Hematol Transfus Cell Ther Año: 2021 Tipo del documento: Article País de afiliación: Brasil